Details : SX-682 was well tolerated with no maximally tolerated dose and no patient discontinued treatment for adverse events. Treatment-emergent adverse events > grade 3 were most common in the 200 and 400 mg dose cohorts, and those related to neutrophils were co...
Brand Name : SX-682
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 09, 2022
Lead Product(s) : SX-682
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial Campaign
Details : Based on the promising results, additional Phase 1/2 trials are now also opening for SX-682 in pancreatic cancer, colorectal cancer, and in advanced tumors including breast and head & neck cancers at various institutes.
Brand Name : SX-682
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2020
Lead Product(s) : SX-682
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
